Leveraging HEOR Services for Drug Development and Market Access in the GCC

Abstract Health economics and outcomes research (HEOR) services play a pivotal role in optimizing research capabilities across healthcare economics, patient outcomes, and policy development. In the Gulf Cooperation Council (GCC) region, applying HEOR principles is essential for driving the pharmaceutical industry toward cost-effective, patient-centered healthcare solutions. The objectives of this commentary are to describe the current trends in HEOR initiatives within the GCC and to highlight related gaps requiring resolution. By supporting drug development and market access, HEOR aids both pharmaceutical companies and payers in crafting sustainable healthcare models that enhance patient access to innovative treatments and contribute to the formulation of resilient healthcare policies. HEOR is also instrumental in assessing advancements in genetics and precision medicine, enabling personalized treatment strategies that optimize therapeutic efficacy based on individual genetic profiles. Additionally, by supporting public and private initiatives, HEOR is committed to promoting equitable access to medical innovations, ensuring that all population segments benefit from novel treatments, irrespective of socioeconomic status. The ultimate goal of HEOR is to drive the adoption of value-based healthcare, a transition that health systems across the Middle East and North Africa region are navigating at different stages, often hindered by barriers requiring resolution at the national level. The core gaps include a shortage of local data and evidence, a low HEOR publication rate, insufficient expertise, and paucity of collaboration.